Travis Sizemore
Rheumatology · Simpsonville, SCNPI 1154760601
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Boehringer Ingelheim at 59.3% of the total. Reporting peaked in 2023 at $6,422 and has fallen 77.8% since, to $1,424 in 2025.
Across 248 payments — averaging $40.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- Amgen$1K
- Novartis$445
- Johnson & Johnson$403
- Pfizer$372
- AbbVie$360
- plus $1K from 19 others
What the payments were for
- Consulting fees$8008%
- Speaking & faculty fees$4,48045%
- Travel & lodging$4575%
- Food & beverage$4,11841%
- Education$1862%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 20 | $5,955 |
| Amgen(2 entities) | 65 | $1,090 |
| Novartis | 26 | $445 |
| Johnson & Johnson | 23 | $403 |
| Pfizer | 26 | $372 |
| AbbVie | 19 | $360 |
| Mallinckrodt Hospital Products Inc. | 14 | $306 |
| UCB, Inc. | 10 | $176 |
| GSK | 6 | $154 |
| E.r. Squibb & Sons, L.L.C. | 5 | $124 |
| AstraZeneca(2 entities) | 5 | $94 |
| Lilly USA, LLC | 5 | $82 |
| Organon | 4 | $79 |
| Radius Health, Inc. | 3 | $66 |
| Genentech USA, Inc. | 3 | $54 |
| Mallinckrodt Enterprises LLC | 3 | $42 |
| Pacira Therapeutics, Inc. | 2 | $39 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Tersera Therapeutics LLC | 1 | $32 |
| Sanofi | 1 | $26 |
| Bristol Myers Squibb | 1 | $19 |
| Sobi, Inc | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$1,600
How this compares
$10,041 in reported general payments places this provider in the 65th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 178 | $1,123,807 |
| Humira PenAdalimumab | 143 | $1,007,514 |
| Humira(Cf) PenAdalimumab | 110 | $860,822 |
| Enbrel SureclickEtanercept | 107 | $766,875 |
| Xeljanz XrTofacitinib Citrate | 89 | $493,565 |
| TavneosAvacopan | 19 | $319,633 |
| Orencia ClickjectAbatacept | 57 | $310,386 |
| OtezlaApremilast | 53 | $254,436 |
| Cosentyx Unoready PenSecukinumab | 32 | $245,882 |
| Enbrel MiniEtanercept | 29 | $215,829 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 22 | $194,428 |
| BenlystaBelimumab | 34 | $155,591 |
| KevzaraSarilumab | 31 | $128,086 |
| Actemra ActpenTocilizumab | 37 | $117,989 |
| SimponiGolimumab | 16 | $101,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $360 | $1,123,807178 claims |
| AmgenTavneos, Otezla, Prolia | $1,090 | $600,43688 claims |
| GSKBenlysta | $154 | $155,59134 claims |
| SanofiKevzara | $26 | $128,08631 claims |
| Johnson & JohnsonSimponi | $403 | $101,33616 claims |
| UCB, Inc.Cimzia (2 Pack) | $176 | $72,66213 claims |
| Lilly USA, LLCForteo | $82 | $46,95912 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $36 | $66221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Simpsonville
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
- Long Huynh-DucGreenville$278K
- Robert KeenanFlorence$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.